Health First-to-Market Edge for Apellis’s Syfovre in Geographic Atrophy Diminished in the Face of an… James Pereira Jul 29, 2023 Exton, Pennsylvania, July 28, 2023 (GLOBE NEWSWIRE) -- For many who have been following the retina market, the news… Read More...
Health Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) James Pereira May 6, 2023 <!-- Name:DistributionId Value:8833066 --> <!--… Read More...
Health Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic… James Pereira Apr 24, 2023 <!-- Name:DistributionId Value:8823381 --> <!--… Read More...
Health Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) James Pereira Mar 7, 2023 <!-- Name:DistributionId Value:8782559 --> <!--… Read More...
Health Apellis Submits Marketing Authorization Application to the European Medicines Agency for… James Pereira Dec 16, 2022 WALTHAM, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global… Read More...
Health Apellis Pharmaceuticals to Present at Upcoming Investor Conferences James Pereira Nov 23, 2022 WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global… Read More...
Health Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results James Pereira Nov 8, 2022 Plans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected… Read More...
Health Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022… James Pereira Nov 1, 2022 WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global… Read More...
Health Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to… James Pereira Oct 1, 2022 New analyses of microperimetry data showed positive trends with both monthly and every-other-month pegcetacoplan… Read More...
Health Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of… James Pereira Sep 30, 2022 WALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global… Read More...